10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exosomal MicroRNA-9-3p Secreted from BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Exosomes, carriers to transfer endogenous molecules, derived from bone marrow-derived mesenchymal stem cells (BMSCs) have been reported to play a role in the progression of bladder cancer. Here we aimed to test the functional mechanism of microRNA-9-3p (miR-9-3p)-containing exosomes derived from BMSCs in bladder cancer. BMSCs were cocultured with bladder cancer cells, and exosomes secreted from BMSCs were identified. Next, the expression of miR-9-3p and endothelial cell-specific molecule 1 (ESM1) in bladder cancer tissues and cells was determined. Then effects of miR-9-3p and ESM1 via BMSC-derived exosomes on bladder cancer cell viability, migration, invasion, and apoptosis were determined by loss- and gain-of-function experiments and on in vivo tumor growth, and metastasis was assessed in nude mice. miR-9-3p expression was decreased and ESM1 was increased in bladder cancer. BMSCs inhibited bladder cancer cell viability, migration, and invasion, and induced apoptosis, whereas the addition of exosome secretion inhibitor GW4869 achieved the opposite effects. Moreover, exosomal miR-9-3p upregulation or ESM1 silencing suppressed bladder cancer cell viability, migration, and invasion; induced cell apoptosis; and inhibited in vivo tumor growth and metastasis. Taken together, BMSC-derived exosomal miR-9-3p suppressed the progression of bladder cancer through ESM1 downregulation, offering a potential novel therapeutic target for bladder cancer therapy.

          Graphical Abstract

          Abstract

          Decreased miR-9-3p expression in bladder cancer reduces the inhibitory effect on endothelial cell-specific molecule 1 (ESM1). Increased ESM1 expression promotes bladder cancer cell proliferation, invasion, and metastasis, and inhibits apoptosis. miR-9-3p-containing exosomes secreted by bone marrow-derived mesenchymal stem cells (BMSCs) decrease the expression of ESM1, and hence inhibit bladder cancer cell proliferation, invasion, and metastasis, and promote apoptosis.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          Bladder cancer.

          Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Aberrant expression of microRNAs in bladder cancer.

            MicroRNAs (miRNAs), a class of small noncoding RNAs, regulate protein-coding gene expression by repressing translation or cleaving RNA transcripts in a sequence-specific manner. A growing body of evidence suggests that miRNAs contribute to bladder cancer development, progression and metastasis. Genome-wide miRNA expression signatures have been used to rapidly and precisely identify aberrant miRNA expression in bladder cancer. Based on reports describing miRNA signatures, several downregulated and upregulated miRNAs have been discovered. Examination of the differential expression of miRNAs between clinical bladder cancer and normal bladder tissue has led to the elucidation of 11 miRNA expression signatures. miRNAs downregulated in bladder cancer, such as miR-145, miR-143 and miR125b, are known to be tumour suppressors, whereas upregulated miRNAs, such as miR-183, miR-96, miR17-5p and miR-20a are oncogenic. Several studies have demonstrated the potential of miRNAs for providing prognostic information. miR-145 is the most frequently downregulated miRNA in bladder cancer and has been shown to significantly inhibit proliferation, migration and invasion. Understanding the role of differentially expressed miRNAs, as well as their molecular targets, in bladder cancer will provide an effective and promising strategy for miRNA-based therapeutics for the treatment of bladder cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.

              Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic subtypes of breast cancer and the molecular subtypes found in other solid tumors. The molecular subtypes in other solid tumors are enriched with specific mutations and copy number aberrations that are thought to underlie their distinct progression patterns, and biological and clinical properties.
                Bookmark

                Author and article information

                Contributors
                Journal
                Mol Ther Nucleic Acids
                Mol Ther Nucleic Acids
                Molecular Therapy. Nucleic Acids
                American Society of Gene & Cell Therapy
                2162-2531
                01 October 2019
                06 December 2019
                01 October 2019
                : 18
                : 787-800
                Affiliations
                [1 ]Department of Urology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, P.R. China
                [2 ]Department of Urology, Suqian First Hospital, Suqian 223800, P.R. China
                [3 ]Department of Radiology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, P.R. China
                [4 ]Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing 210009, P.R. China
                [5 ]Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China
                Author notes
                []Corresponding author Xinwei Wang, Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, No. 42, Baizi Ting, Nanjing 210009, Jiangsu Province, P.R. China. wxwswy@ 123456163.com
                [∗∗ ]Corresponding author Lixin Hua, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing 210029, Jiangsu Province, P.R. China. lixinhua@ 123456njmu.edu.cn
                [6]

                These authors contributed equally to this work.

                Article
                S2162-2531(19)30270-7
                10.1016/j.omtn.2019.09.023
                6861677
                31734559
                0e6aad7a-4580-476c-89e1-cd38e4bb9770
                © 2019 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 22 April 2019
                : 20 September 2019
                Categories
                Article

                Molecular medicine
                microrna-9-3p,bone marrow-derived mesenchymal stem cells,endothelial cell-specific molecule 1,bladder cancer,exosome

                Comments

                Comment on this article